Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Metastatic Cancer
NCT06389123Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Apr 2024
- Primary completion
- Jul 2029
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177-dota-abm-5g and [68Ga]Ga DOTA-5G in metastatic cancer, sponsored by University of California, Davis. Primary endpoint: [68Ga]Ga DOTA-5G PET/CT imaging at 2 hours. Started Apr 2024; status: recruiting.
02
Drugs
lutetium lu 177-dota-abm-5g[68Ga]Ga DOTA-5G
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT06389123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389123.